Sarfaraz Niazi

January 16, 2018

1 Min Read

Since the 2009 enactment of the Biologics Price Competition and Innovation Act (BPCIA) (1), the US Food and Drug Administration (FDA) has licensed six biosimilar products under PHS 351(k) and approved one product under FD&C 505 (b)(2). It also provided complete response letters (CRLs) to four biologics license application (BLA) filings (Table 1) (2). By comparison, the European Medicines Agency (EMA) has approved 31 biosimilar products (3) and refused or withdrawn about five.

There is no doubt that US market entry of biosimilars remains a slow process. Based on my first-hand experience in developing biosimilars for market and teaching about biosimilars over several years, I address herein the most critical questions about the fate of such products in the United States:

  • What key mistakes are biosimilar developers repeating?

  • What are some cost-effective approaches for development of new biosimilars?

  • Is the situation likely to change on the US market for biosimilars in 2018 and beyond?

Just fill out the form to view and download the complete eBook.


Get the eBook Now

You May Also Like